Precision-Guided (MALT-Targeting) Mucosal Vaccines

          By using a new type of screening test to screen a billion candidates from a phage library, a biotech startup company has isolated and sequenced a set of highly aggressive “pathogen pattern” peptides (aka HYPER-pathogen peptides). That is a highly useful result, since these peptide sequences can be added (in low copy numbers) to the surfaces of mucosal vaccine particles, to make them appear to be dangerous pathogens. That appearance of danger will cause specialized immune cells, mounted on the outer surfaces of mucosal membranes, to rapidly pull in and process those dangerous-looking particles, in ways that will trigger and drive – all the way to completion – an immune response that will form antibodies to ANY antigen sequence, derived from ANY pathogen, that is carried (in high copy numbers) on those “MALT-targeting” mucosal vaccines.

          The mucosal membranes in all vertebrate animals have “surface-mounted lymph nodes” (called MALT patches, for “mucosal-associated lymphoid tissues”), as a first line of defense against pathogens which attack and infect mucosal cells. Surface cells called “M cells” are adapted for “sampling” any particles that contact them, to identify – and pull in – those which appear to be dangerous. Rather than processing those particles, an M cell will rapidly hustle and push a particle (enclosed in a membrane bubble) through the cell, and it will eject that particle, in naked form again, into a “docking site” on its “basal” surface.

          When “dendritic” immune cells are formed, specialized cytokine chemo-attractants attract them to the M cell docking sites, and large numbers of dendritic cells settle into those docking sites, to await delivery of a pathogen. If and when a particle is handed to a dendritic cell by an M cell, the dendritic cell will use its surface receptors to analyze that particle, and if the particle has certain types of “pathogen patterns” on its surface – causing it to appear to be both dangerous, and important – that “immature” dendritic cell  will undergo an “activation” (aka maturation or transformation) event, which will transform it into an “antigen-presenting cell”.

          When that happens, the  activated (maturing) dendritic cell will move multiple copies of a special receptor, called the  CCR7 receptor, from inside the cell, to the exposed outer surfaces of the cell. Once they reach the surface, the CCR7 receptors can be contacted and “triggered” by a chemo-attractant cytokine called CCL19, which is gradually and constantly released by T cells in the germinal centers of lymph nodes. An “activated/maturing” dendritic cell will always travel in the direction of the highest number of signals it is receiving from the CCR7 receptors that are distributed all around the cell; and, since the CCL19 molecules are coming from the germinal centers of lymph nodes, that interaction enables activated dendritic cells to eventually find and then enter those lymph nodes.

          While it travels, an activated dendritic cell will “semi-digest” surface proteins from the particle which activated the cell, and it will mount “chunks” of those proteins on special mounting-plaque proteins (MHC proteins). When “antigen presentation” finally occurs, inside a lymph node, B and T cells in the lymph node will take over, and will begin working together to create antibodies that will bind to those antigen sequences, and the dendritic cell will leave the lymph node (possibly in a way that might allow it to revert back into “immature status” again).

          The screening test we created used a combination of: (i) a horizontal filter with 5-micron pore diameters, which is less than half the diameter of a dendritic cell; (ii) a suspension of nasal airway cells, sitting on top of that filter, harvested from mice which had been exposed to 20 million "candidate/contestant" phages per animal, from a phage display library; and, (iii) a supply of the CCL19 chemo-attractant, placed beneath that filter, and diffusing upward through the filter.

          The ONLY cells from the surfaces of the mouse nasal airways which were both ABLE and MOTIVATED to squeeze through the 5 micron pores in the filter, and reach the bottom chamber, were dendritic cells which had been TRANSFORMED into antigen-presenting cells – with their CCR7 receptors moved to their outer surfaces – by their contact with what appeared to be a dangerous and important pathogen. So, we collected those cells, dissolved their membranes, and analyzed the foreign DNA inserts, in the phage particles they were carrying.

          We then hired a phage lab to create genetically-engineered phage particles, with 15 copies/particle of the “MALT-targeting" sequences, and hundreds of copies/particle of a well-known, easy-to-test antigen (the “HA-tag epitope”). “Antibody production tests”, in both mice and pigs, showed that even at the lowest dosages tested, a single nasal infusion of those particles, with no adjuvants added, triggered “robust” formation of not just internal antibodies, but of secreted mucosal antibodies as well, which work via an entirely different mechanism.

          We then shifted over to a different and better type of phage vehicle; we selected an antigen sequence found in numerous strains of influenza viruses which are actively causing problems around the world (the “FI-6” influenza antigen, described in Corti 2011); and, we have already started the first-ever “pathogen challenge tests” to see if those vaccines can actually protect lab animals against a deadly pathogen.

          We will not be ready to formally announce and publish the results of that work, until the results from the pathogen challenge tests become available, hopefully by May 2026. However, we are using this website to quietly share information about what we have done so far, and what we are planning to do next, among small numbers of animal vaccine companies, research experts, and government agencies, in an effort to help give them some advance notice, and an opportunity to begin considering whether they might want to weave this opportunity into their research plans.

          Every result we have been seen to date indicates that this new approach to creating “MALT-targeting” vaccines can provide three new and extremely useful benefits:

1. When applied topically, as mucosal vaccines (such as by nasal spray, or via lollipops or lozenges), they will trigger the formation of both the normal, well-known Y-shaped antibodies that function inside the body, as well as an entirely different class of “secreted antibody dimers” (which work by an entirely different mechanism), into saliva, nasal mucus, lung and genital fluids, and digestive juices, to provide a “first line of defense” against mucosal pathogens (which includes all upper respiratory tract infections, including COVID, and influenza).

2. By using a “targeted transport” system, these vaccines completely eliminate any need for the types of harsh, unpleasant, muscle-irritating “adjuvants” that are required to make injected vaccines effective; and,

3. These vaccines can  eliminate needles, injections, and medical waste, and they do not even require refrigeration. Instead of requiring people to make an appointment, get a shot, and feel soreness at the injection site for 2-3 days afterward, any nurse or group administrator can pass around a bowl of tasty lollipops, to a group of people.

          The startup company which created this new approach to vaccine design has no desire or intent to become a manufacturing company, and we do not have the “biosafety labs” or expertise to perform “pathogen challenge tests”. Instead, we intend to become a licensing company, and will offer (at low cost) customized MALT-targeting phage constructs – carrying any antigen sequence designated by the requester – to any animal vaccine company, vet school research group, government agency, or other qualified research group that will commit to testing those phage constructs in “pathogen challenge tests” in one or more types of animals. To provide incentives and motivation for that type of testing, we hereby offer a worldwide exclusive license – covering MALT-targeting vaccines against one or more specific diseases, in one or more designated types of animals – to the first company or research group which generates enough positive data to support an “animal vaccine registration” (i.e., an approval for sale) by the US Department of Agriculture. More information on that is available via the “Goals and Plans” button in the footer.

          As a final note, before March 2026, the startup company was named Tetraheed Medical LLC, a name that would not trigger attention or scrutiny, to let us “stay under the radar”, and not attract the attention or ire of rivals, competitors, etc.  In March, the company name was changed to Precision-Guided Vaccines LLC. Because that is exactly what we are trying to accomplish, and create; so, starting now, we want everyone to know about us, and what we are doing.

​